ESMO: Cardiff Oncology Falls Despite Onvansertib’s Broad Potential In KRAS-Mutant CRC

Phase II Trial To Initiate In Q4; Data In 2024

 
• By Mandy Jackson

A planned Phase II trial for PLK1 inhibitor onvansertib in KRAS-mutant colorectal cancer may support accelerated approval, but results are two years off and the company cut its prostate cancer plans to conserve cash.

Anatomy of human body with digestive system
Onvansertib generated responses across several KRAS mutations in CRC • Source: Shutterstock

More from Clinical Trials

More from R&D